Prospective, randomised controlled trials (RCTs) that compared dopexamine with a placebo or control in adult patients were eligible for inclusion. Paediatric studies and studies not in English were excluded. The primary outcome measure was all-cause (in-hospital) mortality.
The majority of the included trials included patients who underwent major gastrointestinal, urological and vascular surgery. In included trials, the doses of dopexamine ranged from 0.125 to 2.0 μg/kg-1/min-1. Outcomes assessed included all-cause mortality, 28-day mortality, morbidity, postoperative complications, and gastrointestinal permeability.
Two reviewers independently screened studies for inclusion; there was no disagreement between the reviewers.